A Study of CRD3874-SI in People With Locally Advanced or Metastatic Malignant Solid Tumor

Inclusion Criteria

• Male or female age ≥ 18 years at the time of informed consent
• Be capable, willing, and able to provide written informed consent
• Be willing to comply with clinical trial instructions and requirements, including tumor biopsies (if feasible and required per protocol)
• Patients must have a locally advanced or metastatic cancer, a malignant solid tumor that has progressed on at least one line of systemic therapy or for which no standard treatment is available, the participant is intolerant to available treatment, or the participant declined standard of care systemic therapy
• In the dose escalation phase, patients must have a histologically or cytologically confirmed malignant solid tumor that has progressed on at least one prior standard of care systemic therapy, where available, or declined standard of care systemic therapy
• In the expansion phase patients with the following tumor types will be eligible: Of note patients who declined or were intolerable of standard of care systemic therapy will be considered in all dose expansion cohorts. * Head and neck squamous cell carcinoma (HNSCC) ** Participants must have histologically or cytologically confirmed recurrent and/or metastatic HNSCC and must have received 1-2 prior lines of systemic anti-cancer therapy including a checkpoint inhibitor (patients treated initially with immune checkpoint blockade alone followed by the addition of other drugs in combination [i.e., cytotoxic chemotherapy or EGFR inhibitor], will be considered 1 line of therapy). ** Human papillomavirus (HPV) positive (p16 immunohistochemistry [IHC] positive or HPV ribonucleic acid [RNA] in situ hybridization [ISH] positive), PD-L1 combined positive score (CPS) score high (≥ 1) ** HPV negative (p16 IHC negative or HPV RNA ISH negative), PD-L1 CPS score high (≥ 1) * Adenoid cystic carcinoma (ACC) ** Participants must have histologically or cytologically confirmed recurrent and/or metastatic ACC (cancers arising from non-salivary gland primary sites are eligible) and may have received none or up 2 prior lines of systemic anti-cancer therapy. * Merkel cell carcinoma (MCC) ** Participants must have histologically or cytologically confirmed recurrent and or metastatic MCC and must have received at least one but no more than 3 prior lines of systemic anti-cancer therapy including a checkpoint inhibitor and may not have received prior chemotherapy for MCC. *** Monotherapy alone *** Radiation therapy ** Patients will receive palliative radiation therapy to a tumor site if they have at least one other site of measurable disease that can be chosen as the target lesion to assess response to investigational therapy * Sarcoma that has demonstrated clinical benefit or an objective response to immune checkpoint blockade or sarcoma subtypes that are considered immunogenic subtypes including but not limited to undifferentiated pleomorphic (UPS) or myxofibrosarcoma (MFS), angiosarcoma, alveolara soft part sarcoma, or undifferentiated sarcoma will be considered ** Participants must have histologically or cytologically confirmed locally advanced/metastatic sarcoma and must have received at least one but no more than 2 prior lines of systemic anti-cancer therapy. Patients will receive palliative radiation therapy to a tumor site if they have at least one other site of measurable disease that can be chosen as the target lesion to assess response to investigational therapy. * Melanoma ** Uveal Melanoma *** Participants must have histologically or cytologically confirmed recurrent and/or metastatic uveal melanoma and received at least one but no more than two prior lines of systemic anti-cancer therapy including tebentafusp (if HLA-A 02:01+, unless patient declined or was deemed ineligible) and/or immune checkpoint inhibitor. Melphalan percutaneous hepatic perfusion (PHP) will count as a line of therapy if give on its own. Unlimited partial hepatic directed therapy will be permitted. ** Mucosal and Acral melanoma *** Participants must have histologically or cytologically confirmed recurrent and/or metastatic mucosal or acral melanoma and received at least one but no more than two prior lines of systemic anti-cancer therapy including prior exposure to immune checkpoint inhibition. Patients treated with BRAF-MEK therapy may have up to 3 prior lines of therapy * Non small cell lung cancer ** Participants must have histologically or cytologically confirmed locally advanced/metastatic non-small cell lung cancer with prior exposure to immune checkpoint inhibition and received at least one but no more than 2 prior lines of systemic anti-cancer therapy
• Adequate performance status: Eastern Cooperative Oncology Group (ECOG) 0 or 1/Karnofsky performance status (KPS) 100-70%
• Life expectancy of at least three months after the first CRD3874 infusion, according to the investigator’s opinion
• Presence of measurable disease per RECIST v1.1.Target lesion(s) must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollment
• In the dose expansion phase, participants must agree to have a pretreatment tumor biopsy for research purposes. Participants in whom biopsy is technically not feasible or in whom the associated procedure would result in unacceptable risk, in the opinion of the Investigator, or patients who do not wish to have a biopsy, archival tissue (most recently procured sample where tissue is available) may be used instead, if available
• In the dose expansion phase, participants must agree to on-treatment tumor biopsy for research purposes. Participants in whom biopsy is technically not feasible or in whom would result in unacceptable risk, in the opinion of the investigator, or patients who do not wish to have a biopsy may be exempted from the biopsy requirement with discussion with the principal investigator
• Female subject of childbearing potential (defined as a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy or who has not been naturally postmenopausal for at least 24 consecutive months) should have a negative serum pregnancy testing at screening visit and within 72 hours prior to the first dose of study medication
• Hemoglobin ≥ 9.0 g/dL (within 14 days of treatment initiation)
• Absolute neutrophil count ≥ 1,000/mm^3 (1.0 x 10^9/L) (within 14 days of treatment initiation)
• Platelet count ≥ 100,000/mm^3 (100 x 10^9/L) (within 14 days of treatment initiation)
• Serum bilirubin ≤ 1.2 x upper limit of normal (ULN) OR direct bilirubin ≤ ULN for participants with total bilirubin level > 1.2 x ULN (within 14 days of treatment initiation)
• Aspartate aminotransferase (AST) ≤ 2.5 x ULN OR ≤ 5 x ULN for participants with liver metastases (within 14 days of treatment initiation)
• Alanine aminotransferase (ALT) ≤ 2.5 x ULN OR ≤ 5 x ULN for participants with liver metastases (within 14 days of treatment initiation)
• Albumin ≥ 2.5 mg/dL (within 14 days of treatment initiation)
• Calculated creatinine clearance (CrCl) ≥ 50 mL/min by Cockcroft-Gault formula or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 (within 14 days of treatment initiation)
• International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (within 14 days of treatment initiation)
• Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT and PTT is within therapeutic range of intended use of anticoagulants (within 14 days of treatment initiation)
• Left ventricular ejection fraction (LVEF) > 50%, as measured by echocardiogram (two dimensional [2D]-ECHO) or multi-gated acquisition scan (MUGA) (within 14 days of treatment initiation)

Exclusion Criteria

• Known prior severe hypersensitivity to an investigational product or any component of the study drug therapy’s formulations including polyethylene glycol (PEG), (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v5.0 grade ≥ 3)
• Evidence of clinically significant immunosuppression such as the following: * Primary immunodeficiency state such as severe combined immunodeficiency disease * Concurrent opportunistic infection * Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment. In the setting of non-immune mediated indications for use, chronic/active low dose steroid (equivalent to </= 10mg/day prednisone) use may be permitted at the discretion of the principal investigator. * Current use of immunosuppressive medication, EXCEPT for the following: I. Intranasal, inhaled, ocular, topical steroids, or local steroid injection (e.g., intraarticular injection) II. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent III. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
• Prior organ transplantation, including allogeneic stem-cell transplantation. Consideration will be given to allow patients with a history of autologous transplantation enroll if they are at least 5 years beyond the completion of the transplant pending discussion with the principal investigator
• History or evidence of symptomatic autoimmune disease (e.g., pneumonitis, glomerulonephritis, vasculitis, or other), or history of active autoimmune disease that has required systemic treatment (i.e., use of corticosteroids, immunosuppressive drugs or biological agents used for treatment of autoimmune diseases) in past 2 years prior to enrollment. Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment for autoimmune disease
• Systemic antibiotics received =< 7 days prior to the first dose of study drugs
• Uncontrolled medical condition including current active infection requiring systemic therapy or symptomatic congestive heart failure within 6 months that in the investigators opinion compromise the ability of the patient to complete all study related requirements safely
• Inability to comply with protocol required procedures
• Resting QTc interval by Friderica’s formula >= 470 ms on a 12-lead electrocardiogram (ECG) for males and females
• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment or 5 half-lives, if shorter
• Has had prior chemotherapy or targeted small molecule therapy within 3 weeks, anti-cancer monoclonal antibody (mAb) within 4 weeks or OR 5 half-lives, if shorter, or radiation therapy within 2 weeks prior to the first CRD3874 infusion prior to study day 1 or who has not recovered (i.e., ≤ grade 1 or at baseline) from adverse events due to a previously administered agent * Note: Alopecia or other grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable * Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy
• Evidence of clinically significant interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis related to prior immunotherapy treatment
• History of unstable or deteriorating cardiovascular disease within the previous 6 months prior to screening including but not limited to the following: * Unstable angina or myocardial infarction * Cerebrovascular accident (CVA)/stroke * Congestive heart failure (New York Heart Association [NYHA] class III or IV) * Uncontrolled clinically significant arrhythmias
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases or carcinomatous meningitis may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment
• Has received a live vaccine within 30 days of the planned start of study drug. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist [registered trademark]) are live attenuated vaccines, and are not allowed
• Patients known to be positive for active hepatitis B (hepatitis B virus surface antigen [HBsAg] reactive with detectable hepatitis B virus [HBV] deoxyribonucleic acid [DNA]), or hepatitis C (hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected) * Patients with chronic hepatitis B (positive HBsAg and/or hepatitis B virus core antibody [HBcAb] and negative HBV DNA by polymerase chain reaction [PCR]) are eligible for this study if they are on suppressive anti-viral therapy and deemed safe by a gastroenterologist * Patient who is HCV antibody (Ab) positive but HCV RNA negative due to prior treatment or natural resolution will be considered eligible
• Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) disease that is not controlled. Note HIV-positive patients will be considered eligible if: * Established antiretroviral therapy (ART) for at least four weeks and have an HIV viral load less than 400 copies/mL prior to enrollment * CD4+ T-cell (CD4+) counts ≥ 350 cells/uL * No opportunistic infection within the past 12 months * Has a known history of active TB (Bacillus tuberculosis)
• Women who are pregnant or breastfeeding
• Patients expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through three months after the last dose of study treatment(s)
• Female participants of childbearing potential and male participants who are unwilling to use acceptable method(s) of effective contraception during study treatment and until six months for female and three months for males after the last dose of CRD3874-SI. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant. * (Note: Women not of childbearing potential are defined as: Any female who is postmenopausal [age > 55 years with cessation of menses for 12 or more months or less than 55 years but with no spontaneous menses for at least two years or less than 55 years and spontaneous menses within the past one year but currently amenorrheic (e.g., spontaneous or secondary to hysterectomy) and with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L) or postmenopausal estradiol levels (< 5 ng/dL) or according to the definition of "postmenopausal range" for the laboratory involved] or who have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.)
• The presence of a concurrent active malignancy that in the opinion of the investigator could compromise the conduct of the study or interfere with determining the outcomes of the study objectives
• History of non-infectious colitis